A pharmacokinetic comparison of adult and paediatric formulations of raltegravir in healthy adults

Antiviral Therapy

Volumn 19, Issue 6, 2014, Pages 619-624

  Rhee, Elizabeth G ^a   Rizk, Matthew L ^a   Brainard, Diana M ^a   Gendrano, Isaias N ^a   Jin, Bo ^a,b   Wenning, Larissa A ^a   Wagner, John A ^a   Iwamoto, Marian ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Pfzer Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETHYL CELLULOSE; RALTEGRAVIR; 2 PYRROLIDONE DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHEWABLE TABLET; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG GRANULE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPISTAXIS; FEMALE; FILM COATED TABLET; FLATULENCE; FOOD DRUG INTERACTION; HUMAN; HUMAN EXPERIMENT; INJECTION SITE PAIN; LARYNGITIS; LIPID DIET; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SINGLE DRUG DOSE; SOMNOLENCE; SORE THROAT; STOMATITIS; TABLET; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT; CLINICAL TRIAL; DRUG MONITORING; MEDICINAL CHEMISTRY; MIDDLE AGED; TIME;

ADULT; ANTI-HIV AGENTS; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; DRUG MONITORING; FEMALE; HEALTHY VOLUNTEERS; HUMANS; MALE; MIDDLE AGED; PYRROLIDINONES; TIME FACTORS;

EID: 84902502291     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2765     Document Type: Article

References (9)

1. ISENTRESS (raltegravir). Package insert 2013. Merck & Co., Inc., Whitehouse Station, NJ, USA.
2. Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008; 359:339-354.
3. Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009; 374:796-806.
4. Nachman S, Zheng N, Acosta E, et al. Pharmacokinetics, safety, and 48 week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years. Clin Infect Dis 2014; 58:413-422.
5. Spector SA, Acosta E, Zheng N, et al. Interim results from IMPAACT P1066: raltegravir oral granule formulation in children 6 months to <2 years. 19th Conference on Retroviruses and Opportunistic Infections. 3-6 March 2012, Seattle, WA, USA. Abstract S1001 and poster 987.
6. Brainard DM, Friedman EJ, Jin B, et al. Effect of low-, moderate-, and high-fat meals on raltegravir pharmacokinetics. J Clin Pharmacol 2011; 51:422-427.
7. Merschman SA, Vallano PT, Wenning LA, Matuszewski BK, Woolf EJ. Determination of the HIV integrase inhibitor, MK-0518 (raltegravir), in human plasma using 96-well liquid-liquid extraction and HPLC-MS/MS. J Chromatog B Analyt Technol Biomed Life Sci 2007; 857:15-24.
8. Brainard DM, Wenning LA, Stone JA, Wagner JA, Iwamoto M. Clinical pharmacology profle of raltegravir, an HIV-1 integrase strand transfer inhibitor. J Clin Pharmacol 2011; 51:1376-1402.
9. Rizk ML, Hang Y, Luo WL, et al. Pharmacokinetics and pharmacodynamics of once-daily versus twice-daily raltegravir in treatment-naive HIV-infected patients. Antimicrob Agents Chemother 2012; 56:3101-3106.